Schering-Plough Corporation was an American pharmaceutical company. It was originally the U.S. subsidiary of the German company Schering AG, which was founded in 1851 by Ernst Christian Friedrich Schering. As a result of nationalization, it became an independent company. In 1971, the Schering Corporation merged with Plough, Inc. (founded by Memphis-based entrepreneur Abe Plough in 1908[1]) to form Schering-Plough. On November 4, 2009 Merck & Co. merged with Schering-Plough with the new company taking the name of Merck & Co.
Schering-Plough also owned and operated the major foot care brand name Dr. Scholl's and the skin care line Coppertone. These also became a part of the new company.[3]
As of June 2005[update], Schering-Plough had 1.4% market share in the U.S., placing it seventeenth in the top twenty pharmaceutical corporations by sales compiled by IMS Health.[citation needed]
Plough, Incorporated was founded by the Memphis, Tennessee area entrepreneur Abe Plough (1892–1984) in 1908. He borrowed $125 from his father to start the business at age sixteen. As a one-man business, he mixed "Plough's Antiseptic Healing Oil," a "sure cure for any ill of man or beast," and sold it off a horse-drawn buggy.[1]
Following the entry of the United States into World War II in 1941, U.S. President Franklin Delano Roosevelt ordered Schering AG's U.S. assets be seized. These became the Schering Corporation. The company was placed under a government administratorship until 1952, when it was released, and its assets sold to the private sector.[citation needed]
In 1971, the Schering Corporation merged with Plough, Inc. At the time of the merger, Abe Plough became Chairman of the combined company.[8]
In 2000, Schering-Plough bought a new campus in Summit, New Jersey from Novartis.[citation needed]
On March 12, 2007, Schering-Plough Corp. purchased Organon BioSciences, the drug unit of Netherlands-based Akzo Nobel, for $14.4 billion, giving the US pharmaceutical company an array of women's health products and numerous late-stage pipelines of experimental medicines.[9]Organon itself was founded in 1923 by Dr. Saal van Zwanenberg, the president of Zwanenberg's Slachterijen en Fabrieken.[citation needed]
On November 4, 2009 Schering-Plough merged with Merck & Co. and through a reverse merger, Merck became a subsidiary of Schering-Plough, which renamed itself Merck.[10][11][12][13]
One of Schering-Plough's plants, in Upper Hutt, New Zealand was the largest single site for the production of veterinary vaccines in the world.[citation needed] This was primarily because New Zealand's isolation has formed a natural quarantine, leaving the country free of rabies, foot and mouth, scrapie, bovine spongiform encephalopathy, and many other livestock diseases. It formerly had echinococcosis, but this has been eradicated. The site was known locally as Coopers Animal Health, a trademark which originated in the 1850s with a British company, Cooper & Nephews; the Coopers brand name was still in use by Schering-Plough in Australia, but not elsewhere.[14]
As a result of the acquisition of Organon BioSciences, Schering-Plough bolstered its animal health business with the Akzo Nobel subsidiary Intervet, obtained control of the active pharmaceutical ingredient manufacturer, Diosynth and gained access to human vaccine production through the subsidiary Nobilon. The three companies comprising Organon BioSciences were Organon, Diosynth, and Intervet.[9] HomeAgain continues to use the Intervet name owned by Merck.
After the merger of Schering-Plough with Merck the animal health division was still known as Intervet/Schering-Plough Animal Health.[15] A merger of Merial and Intervet/Schering-Plough was planned in 2010 but was abandoned in March 2011.[16] On June 29, 2011, the company announced that the animal health division would now be known as Merck Animal Health in the United States and Canada; it is now called MSD Animal Health elsewhere in the world.[17]
Nuflor-Florfenicol-for treatment of bovine respiratory disease, foot rot and control of respiratory disease in cattle at high risk of developing bovine respiratory disease.[28]
Schering-Plough also received much publicity for a drug AICAR which mimics the effects of exercise, having especially potent effects when used alongside another drug GW1516 developed by GlaxoSmithKline. [citation needed]
In addition to internal research and development activities Schering-Plough was also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in non-clinical safety assessment was the InnoMed PredTox.[29][30]
In 2004, Schering-Plough was accused of marketing gimmicks and payoffs to doctors for prescribing the company's pharmaceutical products.[31]
Schering-Plough entered a consent decree with the FDA on March 6, 2002 due to manufacturing issues with its albuterol inhaler. It was ordered to pay $500 million US dollars to the US Treasury.[32]
^Merck & Company, Inc. (November 12, 2009). "Notice of Reorganization Event". Posted on Thomson Reuters web site. Archived from the original(PDF) on February 1, 2016. Retrieved 2009-11-13.
^"About Us". Coopers Animal Health. Archived from the original on 23 March 2016. Retrieved 23 March 2016.
